Logo

Merck Extends License to GeneGo s MetaCore and MetaBase by Two Years

Jan 09, 2006

NEW YORK, Jan. 9 (GenomeWeb News) - Merck has extended its global enterprise agreement with GeneGo for its data-mining suite for two more years, GeneGo said today.

 

Merck researchers will continue to use GeneGo's MetaCore data-mining suite in research and development activities.

 

They will also retain direct access to MetaBase, a database of mammalian protein interactions, signaling and metabolic pathways, bioactive compounds, and diseases manually curated by GeneGo from full text experimental literature.

 

MetaCore and MetaBase have been integrated with Merck's discovery informatics platform and are used across multiple therapeutic areas.

 

Financial details were not disclosed.

Breaking News
The Scan

Genetic Tests Lead to Potential Prognostic Variants in Dutch Children With Dilated Cardiomyopathy

Researchers in Circulation: Genomic and Precision Medicine found that the presence of pathogenic or likely pathogenic variants was linked to increased risk of death and poorer outcomes in children with pediatric dilated cardiomyopathy.

Fragile X Syndrome Mutations Found With Comprehensive Testing Method

Researchers in Clinical Chemistry found fragile X syndrome expansions and other FMR1 mutations with ties to the intellectual disability condition using a long-range PCR and long-read sequencing approach.

Team Presents Strategy for Speedy Species Detection in Metagenomic Sequence Data

A computational approach presented in PLOS Computational Biology produced fewer false-positive species identifications in simulated and authentic metagenomic sequences.

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.